$VCYT
Veracyte Inc Stock $vcyt

$vcyt Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000143774920022261 Filed on November 02, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$34.54M	$31.12M	$30.97M
YoY Change	16.17%	0.48%	31.99%
Cost Of Revenue	$11.19M	$10.37M	$9.114M
YoY Change	10.57%	13.78%	10.33%
Gross Profit	$23.35M	$20.75M	$21.86M
YoY Change	19.07%	-5.07%	43.76%
Gross Profit Margin	67.61%	66.68%	70.57%
Selling, General & Admin	$25.15M	$19.50M	$19.71M
YoY Change	12.28%	-1.07%	24.58%
% of Gross Profit	107.71%	93.98%	90.18%
Research & Development	$4.530M	$4.042M	$3.643M
YoY Change	3.66%	10.95%	6.55%
% of Gross Profit	19.4%	19.48%	16.67%
Depreciation & Amortization	$2.020M	$1.990M	$970.0K
YoY Change	57.81%	105.15%	-1.02%
% of Gross Profit	8.65%	9.59%	4.44%
Operating Expenses	$31.42M	$23.54M	$23.36M
YoY Change	12.98%	0.8%	21.38%
Operating Profit	-$8.070M	-$4.066M	-$1.763M
YoY Change	-1.59%	130.63%	-59.04%
Interest Expense	-$50.00K	$55.00K	$58.00K
YoY Change	-37.5%	-5.17%	-88.35%
% of Operating Profit
Other Income/Expense, Net	$80.00K	-$58.00K	$1.091M
YoY Change	-90.24%	-105.32%	227.63%
Pretax Income	-$8.040M	-$4.124M	-$730.0K
YoY Change	7.77%	464.93%	-83.67%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.044M	-$4.124M	-$730.0K
YoY Change	7.86%	464.93%	-83.67%
Net Earnings / Revenue	-23.29%	-13.25%	-2.36%
Basic Earnings Per Share		-$0.08
Diluted Earnings Per Share	-$138.5K	-$0.08	-$15.02K
COMMON SHARES
Basic Shares Outstanding	57.90M	54.86M shares	48.45M shares
Diluted Shares Outstanding		54.86M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$349.4M	$345.1M	$195.7M
YoY Change	119.33%	76.34%	151.54%
Cash & Equivalents	$349.4M	$345.1M	$195.7M
Short-Term Investments
Other Short-Term Assets	$3.200M	$3.200M	$2.200M
YoY Change	45.45%	45.45%	22.22%
Inventory	$4.657M	$4.456M	$6.608M
Prepaid Expenses
Receivables	$18.46M	$17.63M	$23.61M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$375.7M	$370.3M	$228.1M
YoY Change	100.16%	62.36%	139.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.990M	$8.914M	$8.488M
YoY Change	0.64%	5.02%	-5.05%
Goodwill	$2.725M	$2.725M	$1.057M
YoY Change	0.0%	157.81%	0.0%
Intangibles	$59.92M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.399M	$2.303M	$1.228M
YoY Change	-2.64%	87.54%	46.71%
Total Long-Term Assets	$81.48M	$83.84M	$32.23M
YoY Change	-6.9%	160.13%	35.97%
TOTAL ASSETS
Total Short-Term Assets	$375.7M	$370.3M	$228.1M
Total Long-Term Assets	$81.48M	$83.84M	$32.23M
Total Assets	$457.2M	$454.2M	$260.3M
YoY Change	66.11%	74.47%	118.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.116M	$1.932M	$5.568M
YoY Change	33.85%	-65.3%	373.87%
Accrued Expenses	$11.71M	$10.45M	$9.760M
YoY Change	-14.77%	7.02%	5.39%
Deferred Revenue	$371.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change
Total Short-Term Liabilities	$16.78M	$13.92M	$16.77M
YoY Change	-3.94%	-17.01%	60.71%
LONG-TERM LIABILITIES
Long-Term Debt	$810.0K	$756.0K	$639.0K
YoY Change	16.71%	18.31%	-97.46%
Other Long-Term Liabilities	$0.00	$16.80M	$11.90M
YoY Change	-100.0%	41.18%	197.5%
Total Long-Term Liabilities	$810.0K	$756.0K	$639.0K
YoY Change	16.71%	18.31%	-97.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.78M	$13.92M	$16.77M
Total Long-Term Liabilities	$810.0K	$756.0K	$639.0K
Total Liabilities	$35.93M	$31.43M	$29.28M
YoY Change	0.49%	7.32%	-26.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$281.6M	-$273.6M	-$239.2M
YoY Change	14.15%	14.35%	3.57%
Common Stock	$702.8M	$696.3M	$470.3M
YoY Change	44.57%	48.06%	51.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$421.2M	$422.7M	$231.0M
YoY Change
Total Liabilities & Shareholders Equity	$457.2M	$454.2M	$260.3M
YoY Change	66.11%	74.47%	118.6%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$8.044M	-$4.124M	-$730.0K
YoY Change	7.86%	464.93%	-83.67%
Depreciation, Depletion And Amortization	$2.020M	$1.990M	$970.0K
YoY Change	57.81%	105.15%	-1.02%
Cash From Operating Activities	$2.260M	$1.750M	-$1.550M
YoY Change	26.26%	-212.9%	-13.41%
INVESTING ACTIVITIES
Capital Expenditures	-$890.0K	-$640.0K	-$240.0K
YoY Change	-19.09%	166.67%	-63.64%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$1.000M	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$890.0K	-$1.640M	-$220.0K
YoY Change	-97.83%	645.45%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$193.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.920M	197.5M	4.790M
YoY Change	-1.68%	4023.38%	-91.53%
NET CHANGE
Cash From Operating Activities	2.260M	1.750M	-1.550M
Cash From Investing Activities	-890.0K	-1.640M	-220.0K
Cash From Financing Activities	2.920M	197.5M	4.790M
Net Change In Cash	4.290M	197.6M	3.020M
YoY Change	-111.81%	6443.71%	-94.42%
FREE CASH FLOW
Cash From Operating Activities	$2.260M	$1.750M	-$1.550M
Capital Expenditures	-$890.0K	-$640.0K	-$240.0K
Free Cash Flow	$3.150M	$2.390M	-$1.310M
YoY Change	9.0%	-282.44%	15.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	345080000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17629000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19329000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	4456000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6806000	USD
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57897321
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57813833
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3150000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2235000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	370315000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	187687000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8914000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	627000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8933000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8094000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8808000	USD
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	61197000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2385000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	65019000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	2725000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	2725000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4124000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-730000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2303000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1437000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26865000	USD
CY2020Q3	us-gaap	Assets Assets	454151000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Assets Assets	275212000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1932000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2328000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10445000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5141000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1542000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1407000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13919000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4042000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17469000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	756000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	694000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6420000	USD
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57813833
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49625341
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49625341
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	13169000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	13169000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9208000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	6088000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10331000	USD
CY2020Q3	vcyt	Number Of Disease Areas With Genomic Testing NumberOfDiseaseAreasWithGenomicTesting	4	pure
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11506000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	31426000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90638000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	35757000	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48588296
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51632750
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45141502
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1091000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	226147000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193831000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3329000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	50000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	696217000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	486090000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273550000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246685000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	422725000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	454151000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275212000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31121000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30973000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82947000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3643000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12618000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10408000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10955000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13088000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	39240000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	39508000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8546000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6624000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24316000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20448000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1274000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	267000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3822000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	800000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	35187000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	32736000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	110264000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	97568000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4066000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1763000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27317000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6930000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	55000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	58000	USD
	us-gaap	Interest Expense InterestExpense	175000	USD
	us-gaap	Interest Expense InterestExpense	596000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54858052
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	935000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	728000	USD
CY2020Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	483000	USD
CY2020Q3	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	3032000	USD
CY2020Q3	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	15000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	43000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4124000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	422725000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	239455000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	193831000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8074000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2037000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3161000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	8591000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	35000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26865000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	422725000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	224240000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4232000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	774000	USD
CY2019Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	132000	USD
CY2019Q3	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	2324000	USD
CY2019Q3	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	62000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	254000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-730000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	231024000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	79755000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	137848000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11141000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1266000	USD
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	810000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Employee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionEmployee	6255000	USD
	vcyt	Adjustments To Additional Paid In Capital Sharebased Compensation Increase For Cost Recognition Nonemployee AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationIncreaseForCostRecognitionNonemployee	138000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	572000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5141000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	231024000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26865000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5141000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5919000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2836000	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-0	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	23000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9354000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6965000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	83000	USD
	vcyt	Interest Expense On Endof Term Debt Obligation InterestExpenseOnEndofTermDebtObligation	162000	USD
	vcyt	Interest Expense On Endof Term Debt Obligation InterestExpenseOnEndofTermDebtObligation	174000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1088000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	vcyt	Noncash Portion Of Lease Expense NoncashPortionOfLeaseExpense	714000	USD
	vcyt	Noncash Portion Of Lease Expense NoncashPortionOfLeaseExpense	810000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	332000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	17000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1742000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	142000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10445000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1262000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3206000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	923000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-185000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-134000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2505000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3300000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1258000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11972000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5022000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1949000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1656000	USD
	vcyt	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiability	1040000	USD
	vcyt	Increase Decrease In Operating Lease Right Of Use Asset Lease Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiability	881000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-534000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1000000	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	-0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2949000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1633000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193831000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137848000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	100000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	24900000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-0	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	229000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3161000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	810000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10114000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12413000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200684000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124322000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	185763000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	117667000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78598000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345683000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	196265000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	355000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	821000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3000	USD
	us-gaap	Interest Paid Net InterestPaidNet	330000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	345080000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	159317000	USD
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	603000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	345683000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	159920000	USD
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	23.25
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137800000	USD
CY2019Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9200000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i><b>Reclassifications</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Certain prior period balances have been reclassified to conform to current period presentation of the Company’s condensed consolidated financial statements and accompanying notes. Such reclassifications have <em style="font: inherit;">no</em> effect on previously reported results of operations, accumulated deficit, subtotals of operating, investing or financing cash flows or consolidated balance sheet totals; however, for the period ended <em style="font: inherit;"> September 30, 2019</em>, the Company reclassified $810,000 of changes in operating assets and liabilities to noncash lease expense in the statement of cash flows.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The preparation of unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Items subject to such estimates include: revenue recognition; write-down of supplies; the useful lives of property and equipment; the recoverability of long-lived assets; the incremental borrowing rate for leases; the estimation of the fair value of intangible assets and contingent consideration; variable interest entity assessment; impairment of equity investment, at cost; stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; reserve on accounts receivable and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates and assumptions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6900000
CY2020Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	30.00
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193800000	USD
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	13200000	USD
CY2020Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Cumulative Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount	0	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Concentrations of Credit Risk and Other Risks and Uncertainties</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The worldwide spread of coronavirus, or COVID-<em style="font: inherit;">19,</em> has created significant uncertainty in the global economy. There have been <em style="font: inherit;">no</em> comparable recent events that provide guidance as to the effect the spread of COVID-<em style="font: inherit;">19</em> as a global pandemic <em style="font: inherit;"> may </em>have, and, as a result, the ultimate impact of COVID-<em style="font: inherit;">19</em> and the extent to which COVID-<em style="font: inherit;">19</em> impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and difficult to predict. If the financial markets or the overall economy are impacted for an extended period, the Company’s liquidity, revenues, supplies, goodwill and intangibles <em style="font: inherit;"> may </em>be adversely affected. The Company considers the effects of COVID-<em style="font: inherit;">19</em> pandemic in developing our estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The majority of the Company’s cash and cash equivalents are deposited with <em style="font: inherit;">one</em> major financial institution in the United States. Deposits in this institution <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits of cash and cash equivalents.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Several of the components of the Company’s sample collection kits and test reagents, and the nCounter system and related diagnostic kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company is also subject to credit risk from its accounts receivable related to its sales. Credit risk for accounts receivable from testing revenue is incorporated in testing revenue accrual rates as the Company assesses historical collection rates and current developments to determine accrual rates and amounts the Company will ultimately collect. The Company generally does <em style="font: inherit;">not</em> perform evaluations of customers’ financial condition for testing revenue and generally does <em style="font: inherit;">not</em> require collateral. The Company assesses credit risk and the amount of accounts receivable the Company will ultimately collect for product, biopharmaceutical and collaboration revenue based on collection history, current developments and credit worthiness of the customer. The estimate of credit losses is <em style="font: inherit;">not</em> material at <em style="font: inherit;"> September 30, 2020</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Through <em style="font: inherit;"> September 30, 2020</em>, most of the Company’s revenue has been derived from the sale of Afirma. To date, Afirma has been delivered primarily to physicians in the United States. The Company’s <em style="font: inherit;">third</em>-party payers and other customers in excess of <em style="font: inherit;">10%</em> of total revenue and their related revenue as a percentage of total revenue were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended September 30,</em></em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</em></em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2019</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">2019</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medicare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">24</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Johnson and Johnson Services, Inc.</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">UnitedHealthcare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">35</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">Less than <em style="font: inherit;">10%</em></sup></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Company’s <em style="font: inherit;">third</em>-party payers and other customers in excess of <em style="font: inherit;">10%</em> of accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows at the following dates:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">September 30, 2020</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><em style="font: inherit;">December 31, 2019</em></b></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Johnson and Johnson Services, Inc.</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Medicare</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">UnitedHealthcare</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;"></em></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less than 10%</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p>
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5399174
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6131463
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5641543
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6286530
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2543000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2614000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	11873000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1542000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10331000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8382000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10100000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2063000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3634000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10445000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13734000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	588000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2401000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2472000	USD
CY2020Q3	vcyt	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	4227000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14845000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2972000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1400000	USD
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5279277
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5562484
CY2020Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9886980
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7690456

Files In Submission

Name	View Source	Status
0001437749-20-022261-index-headers.html	Edgar Link	pending
0001437749-20-022261-index.html	Edgar Link	pending
0001437749-20-022261.txt	Edgar Link	pending
0001437749-20-022261-xbrl.zip	Edgar Link	pending
ex_197467.htm	Edgar Link	pending
ex_197468.htm	Edgar Link	pending
ex_197469.htm	Edgar Link	pending
ex_197470.htm	Edgar Link	pending
ex_207290.htm	Edgar Link	pending
ex_207336.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcyt-20200930.xsd	Edgar Link	pending
vcyt-20200930_cal.xml	Edgar Link	unprocessable
vcyt-20200930_def.xml	Edgar Link	unprocessable
vcyt-20200930_lab.xml	Edgar Link	unprocessable
vcyt-20200930_pre.xml	Edgar Link	unprocessable
vcyt20200930_10q.htm	Edgar Link	pending
vcyt20200930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCYT
Veracyte Inc Stock $vcyt

2020 Q4 Form 10-Q Financial Statement

#000143774920022261 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT Veracyte Inc Stock $vcyt

2020 Q4 Form 10-Q Financial Statement

#000143774920022261 Filed on November 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCYT
Veracyte Inc Stock $vcyt